Introduction
With prevalence rates estimated at 0.5 to 2.0 % for trichotillomania and 1.4 to 5.4 % for skin picking disorder, these body-focused repetitive behavior disorders (BFRBs) represent common and oftentimes disabling health problems [1] [2] [3] [4] [5] [6] . Characterized by persistent and recurrent patterns of excessive grooming, trichotillomania, and skin picking disorder are frequently associated with impaired functioning, reduced quality of life, poor self-esteem, and even medical complications such as trichobezoars and infections [7] [8] [9] [10] [11] [12] . Whereas trichotillomania usually has its onset in late childhood or early adolescence [13, 14] , skin picking disorder has a more varied onset in either childhood, adolescence, or adulthood [8, 15] . Both disorders have been described as chronic, relapsing conditions, and both often have worsening symptom severity during times of stress, anxiety, or boredom [8, 14] . Even though trichotillomania and skin picking disorder interfere with a person's quality of life, the majority (about 65 %) of individuals never seek treatment [9, 16] .
Research into the neurobiology of BFRBs is still in an early stage, but our current understanding of these disorders owes much to understanding animal behaviors that are similar to BFRBs [17] [18] [19] and to the early human research in these disorders [20] . Although still incompletely understood, recent advances in the treatment of BFRBs show that trichotillomania and skin picking disorder can often be effectively treated with pharmacologic interventions.
Neurobiology Genetic vulnerability
Although much remains unknown about the neurobiological underpinnings of BFRBs, recent genetic evidence suggests a complex picture for these two disorders. Trichotillomania appears to be familial with heritability estimates ranging from 0.32 to 0.78 [21, 22] . One study also found that 1.2 % of twins (n=2518 twins) from the UK Adult Twin Registry endorsed clinically significant skin picking and that additive and non-additive genetics factors accounted for more than 40 % of the variance in picking [23] . While this research suggests that both disorders have familial aspects, a recent study questions whether a genetic link exists across BFRBs. A recent family study of 110 proband cases with trichotillomania, 128 first-degree relatives of the probands, 48 controls, and 50 first-degree relatives of the controls found that case versus control relatives had higher recurrence risk estimates for trichotillomania but not skin picking disorder [24] . These findings seem to support the idea that BFRBs may not simply be variants of the same disorder, and it also calls into question a shared biological relationship between these disorders. Although we currently tend to use the same pharmacological treatments for both disorders, this recent genetic and family data may suggest that different treatment could be necessary for different BFRBs.
Neuroimaging studies
Recent neuroimaging studies in trichotillomania have shed light on possible biological correlates to the behavior. Structural studies in trichotillomania have been largely mixed and suggest that the disorder may be more heterogeneous than initially thought. A study examining cortical thickness in 12 individuals with trichotillomania, their first-degree relatives (n=10) and controls (n=14) found excessive cortical thickness in probands and their relatives in brain regions associated with inhibitory control and action monitoring [25•] . A different study, however, found reduced cortical thickness in a different area (the right parahippocampal gyrus which is involved in memory and recognition of social context) in 17 subjects with trichotillomania [26••] . A recent functional neuroimaging study found that 12 individuals with trichotillomania exhibited decreased activation of the nucleus accumbens when present with a task of reward anticipation but showed increased activity when presented with gain and loss outcomes [27] .
In the case of skin picking disorder, a recent structural study in 17 women with skin picking disorder found altered brain volume and cortical thickness in a number of frontal areas involved in habit formation, and these findings differed from individuals (n=17) with trichotillomania [26••] . Other neuroimaging studies, however, have found similar disorganization of white matter tracts underlying motor generation and suppression in both disorders [28, 29] .
Taken together, the neuroimaging research suggests that dysfunction in circuits involved in top-down control may be implicated in BFRBs. Having said that, the various inconsistent findings in these studies suggest that there may be significant heterogeneity among individuals with the same disorder and in many cases, this may explain why findings between disorders have also been inconsistent.
Treatment
Traditionally, trichotillomania and skin picking disorder have been treated with behavioral therapy, and two recent meta-analyses support the choice of behavioral therapy as the first-line treatment [30, 31] . Emerging evidence, however, suggests that trichotillomania and skin picking disorder can be treated successfully with pharmacotherapy as well.
Pharmacotherapy
Although no pharmacotherapies are FDA-approved for trichotillomania or skin picking disorder, there have been 15 double-blind, placebo-controlled studies for these disorders (Table 1) . Several important findings have emerged from these studies. First, serotonin reuptake inhibitors (clomipramine and the selective serotonin reuptake inhibitors [SSRIs]) have shown mixed results in studies, with clomipramine demonstrating some benefit for trichotillomania and the SSRIs showing some positive effects in skin picking disorder. Methodological problems with the skin picking studies and small sample sizes with the trichotillomania studies, however, limit the interpretation of these mixed results. It is possible therefore that some individuals with either of these disorders will respond to SSRIs, but the evidence as a whole does not suggest that they will be effective for the core symptoms of trichotillomania, except possibly clomipramine. In the case of skin picking, the SSRIs may be more beneficial but the studies are limited and all were conducted before there were clear diagnostic criteria for the disorder. It is also possible that the Bresponse^many people derive from SSRIs is a reduction in their anxiety or an improvement in mood. As both anxiety and depression may worsen pulling or picking behavior, it stands that the SSRIs may indirectly be assisting with the BFRB behavior. In the case of trichotillomania, it does not seem that the SSRIs have any direct effect on the pulling in a majority of cases. In the case of skin picking disorder, SSRIs may be more beneficial.
The second important finding from these early studies was that behavioral therapy appears to be more effective than serotonergic antidepressant treatment. Two comparison studies have been conducted in trichotillomania. In the 
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first study, clomipramine was compared to cognitive behavioral therapy (a modified form of habit reversal therapy) [32] . Cognitive behavioral therapy was significantly more effective in reducing the symptoms of trichotillomania than either clomipramine or placebo. In a second comparison study of fluoxetine with behavior therapy, behavior therapy resulted in statistically significant reductions in trichotillomania symptoms compared with either fluoxetine or wait-list [33] . One study, however, found that a combination of behavior therapy (habit reversal therapy) with a serotonergic antidepressant (sertraline) was more beneficial than either modality by itself [34] . Given the findings from these early studies examining antidepressant medications for BFRBs, recent pharmacotherapy research has shifted its focus to other agents. One area of particular interest has been glutamate agents such as n-acetylcysteine (NAC). A study of NAC versus placebo in 50 adults found that NAC was effective in reducing pulling episodes and improving the ability to resist the urge to pull [35] . A study in 39 children with trichotillomania, however, found no significant differences between NAC and placebo [36•] . The inconsistent findings from these two studies raise multiple questions that may prove useful in focusing treatment research. For example, are children with BFRBs different biologically from adults? Younger children with trichotillomania are generally less likely to report urges to pull, and this clinical phenomenon of urges seems to increase with age [37] . Therefore, perhaps NAC works best in individuals with BFRBs who report urges preceding their behavior. This would be consistent with the literature examining NAC in drug addiction [38] . If NAC works by reducing urges to pull or pick, then this might allow for clinical subtyping as a means of refining treatment approaches.
Other recent pharmacological research further supports subtyping individuals with BFRBs as a way to improve treatment outcomes. Opioid antagonists (e.g., naltrexone) are a class of medications that have been used successfully in animals with excessive grooming (for example, acral lick dermatitis in dogs) [39] . A recent double-blind placebo-controlled study of naltrexone in 52 adults with trichotillomania, however, demonstrated that naltrexone was no more successful than placebo in treating trichotillomania [40••] . A post hoc analysis found that naltrexone was more effective than placebo in those individuals with trichotillomania who exhibited cognitive inflexibility on testing (using the intradimensional/extradimensional shift task) and those who reported a family history of alcohol or substance use disorders in first-degree relatives [40••] .
Second-generation antipsychotics may also play a role in the treatment of BFRBs. An earlier study examining olanzapine in 25 adults with trichotillomania found that 11 of 13 (85 %) individuals assigned to olanzapine and only 2 of 12 (17 %) assigned to placebo responded to treatment [41] . Building upon this finding, a recent open-label study examining aripiprazole in 12 individuals with trichotillomania found it to be effective in 7 subjects (58 %) in reducing hair pulling frequency [42] . This latter study needs to be evaluated cautiously given the openlabel nature of the design. The two studies together not only suggest a potential role for antipsychotics in treating BFRBs but they also raise several questions. Given that not all antipsychotics have a similar mechanism of action, which ones would be most useful for BFRBs? In addition, if they are successful, mechanistically how are they helping? Is it possible that these medications dampen reward-driven behaviors through their effects on dopamine in the nucleus accumbens, and this would be consistent with one of the recent neuroimaging studies [27] . Further subtyping using fMRI may be promising to see who responds preferentially to certain antipsychotic medications.
Finally, other BFRB treatment studies are attempting to use findings from neuroimaging to enhance pharmacological approaches. The neuroimaging data in BFRBs suggest disorganization of white matter tracts in motor habit generation and suppression [28, 29] . On a neurochemical level, these motor habits may rely at least partially on the endocannabinoid system. Thus, one study examined the cannabinoid agonist, dronabinol, in an open-label study of 14 individuals with trichotillomania. The study found that trichotillomania symptoms improved significantly in a majority (64.3 %) of subjects [43] . Future research may want to examine whether dronabinol works preferentially in individuals with BFRBs who also have disorganized white matter tracts in the relevant motor areas of the brain.
The results of all of these studies suggest that a single pharmacological treatment for everyone with trichotillomania and skin picking disorder is highly unlikely. Instead, identifying subtypes of individuals with BFRBs, using clinical, cognitive, and neuroimaging research, may allow for targeted and more effective pharmacotherapy.
Conclusions
Although there are several studies of pharmacotherapy for trichotillomania and skin picking disorder, the data are either limited or inconsistent. The two pharmacotherapies that have shown potential promise in treating adult trichotillomania in double-blind, placebo-controlled studies are NAC and olanzapine. Open-label studies show the promise of both aripiprazole and dronabinol in reducing trichotillomania symptoms. In addition, a single study suggests that medication in combination with behavioral therapy may be a more successful option than either one alone. In the case of skin picking, the SSRIs may play a role in treatment. Because different pharmacotherapies with different neurobiological mechanisms of action (glutamate in the nucleus accumbens, dopamine blockade, cannabinoid agonism, serotonergic tone) have all shown promise for BFRBs, these findings force us to consider whether there may be meaningful subtypes of BFRBs with different pathophysiologies. If that is the case, then pharmacological interventions will need to be individually tailored based on this information.
In the area of BFRBs, the systematic study of treatment efficacy and tolerability is in its infancy. With few studies published, and none that have been successfully replicated by other investigators, it is not possible to make treatment recommendations with a substantial degree of confidence. Nonetheless, specific drug therapies offer promise for the effective treatment of BFRBs. However, most published studies have employed relatively small sample sizes, are of limited duration, and involve possibly non-representative clinical groups (e.g., those without co-occurring psychiatric disorders). In addition, heterogeneity of treatment samples may also complicate identification of effective treatments. At present, issues such as which medication to use and for whom cannot be sufficiently addressed with the available data.2333
